1. BioNTech (BNTX -1.68%):
BioNTech stock has fallen nearly 32% this year, mainly attributed to declining sales of their co-marketed COVID-19 vaccine, Comirnaty. In the first nine months of 2023, BioNTech’s total revenue was less than one-fifth of the prior year’s level.
Despite this downturn, analysts are optimistic about BioNTech’s future. The average 12-month price target indicates a potential upside of around 36%, while the most bullish analyst predicts a surge of over 150%. The hope rests on BioNTech’s pipeline, particularly their late-stage candidates, influenza vaccine BNT161, and cancer immunotherapy BNT316.
2. JD.com (JD 4.46%):
Chinese e-commerce giant JD.com has experienced a significant drop of almost 50% in 2023. However, most analysts remain bullish on the stock, with 32 out of 37 surveyed recommending it as a buy or strong buy. Only one analyst advises selling JD.com shares.
The average 12-month price target indicates a potential increase of 61% from the current share price. Some attribute this optimism to JD.com’s attractive valuation, with a forward earnings multiple of less than 7.9. Analysts believe there is ample opportunity for the stock to rebound.
3. Moderna (MRNA 0.16%):
Similar to BioNTech, Moderna has faced challenges this year, resulting in a share price drop of over 50%. However, analysts foresee a potential recovery in 2024. The average 12-month price target suggests an increase of nearly 50%.
Moderna’s positive phase 2b study results for mRNA-4157 in combination with Keytruda in treating melanoma have buoyed hopes. Additionally, the anticipation of launching the respiratory syncytial virus (RSV) vaccine next year has further raised expectations.
While analysts’ price targets may not always materialize, the long-term prospects for BioNTech, JD.com, and Moderna appear favorable. However, it’s important to note that the projected skyrocketing growth anticipated by Wall Street may not materialize as expected in 2024.